Intensity Therapeutics, Inc. (INTS) is a Healthcare stock trading at $4.87 (as of 2026-08-21), with a market capitalization of $15.88M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer. The company was founded in 2012 and is headquartered in Westport, Connecticut.
Intensity Therapeutics is a clinical-stage biotech developing and commercializing cancer drugs, with INT230-6 in Phase 2 for refractory solid tumors, and it also runs a Merck collaboration to evaluate INT230-6 plus Keytruda in advanced cancers.
With reported revenue of 0.0B and an operating margin of -2687.2% for the latest quarter shown (2026-03-31), the core profit driver is future commercialization value unlocked by clinical success for INT230-6, potentially amplified by collaboration-related development activity with Merck.
Business quality (Weak): Clear clinical-stage focus (INT230-6 Phase 2, multiple cancer types) and measurable trial outcome KPIs are provided, but the latest quarter shows 0.0B revenue and very large operating losses, so near-term economics are not yet supported by product sales.
| Price | $4.87 |
| Market Cap | $15.88M |
| Price / Book | 1.72 |
| Price / Sales | 49.02 |
| Revenue (TTM) | $180000.00 |
| Net Margin | -6447.8% |
| Revenue Growth (YoY) | -42.7% |
| EPS Growth (YoY) | 631.6% |
| Altman Z-Score | -6.34 (distress) |
| Sector P/E (Healthcare) | 21.7 |
| Industry P/E (Pharmaceutical Products) | 17.2 |
| Top Institutional Holder | VANGUARD GROUP INC ($266125.00) |
| Institutional Holders Tracked | 10 |
| Sector | Healthcare |
| Industry | Pharmaceutical Products |
| CEO | Lewis H. Bender |
| Employees | 5 |
| Country | US |
| IPO Date | 2023-06-30 |
Data as of 2026-08-21.
Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.